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To the editor: I read with great interest the article by Menc-
zer et al. [1] on the outcome prediction before neoadjuvant 
chemotherapy (NAC) in ovarian cancer. In the study, the 
authors indicated that progression free survival (PFS) of ovar-
ian cancer patients who underwent NAC was not different 
between marked improvement group and no/some improve-
ment group. The median PFS of the two groups were 7.9 and 
7.2 months. Of course, as the authors addressed, the small size 
of this study may not provide enough evidence to draw any 
meaningful conclusion. However, as a hypothesis-developing 
study, this study raised several important hypotheses that 
should be considered in the future studies on the role of NAC 
in ovarian cancer.
First, this study suggested no meaningful correlation be-
tween the response to NAC and clinical outcome, i.e., PFS, 
after interval debulking. The short PFS in this study may not 
be surprising because they gave NAC to the selected high-risk 
patients by criteria suggested by Nelson et al. [2], i.e., exten-
sive upper abdominal disease and/or extraperitoneal disease. 
As the authors did not observe any difference of PFS between 
good vs. poor responders, this result may be interpreted as a 
challenge to the role of NAC in patients with extensive tumor 
burden. Although the authors did not compare the rate of 
successful cytoreduction between good and poor respond-
ers, it is obvious that surgical cytoreduction would be easier in 
good responders to NAC. This may imply that enhanced fea-
sibility of cytoreduction provided by NAC may have no role in 
these setting, especially in terms of prognosis. This interesting 
observation should be confirmed in further studies.
In addition, it should be also noted that CA-125 decreased 
more than 50% in all patients in the study. Thus, it is possible 
that all patients may be similarly benefited by NAC in terms 
of surgical resectability. If this is the case, the cytoreduction 
outcome between good and poor responders may not be 
dramatically different in this study. Personally, I experienced 
that more than 50% CA-125 reduction is sufficient to increase 
feasibility of cytoreduction in patients with extensive tumor 
burden. Therefore, I would like to indicate that the cutoff di-
viding ‘no/some improvement’ and ‘marked improvement’ 
group may be arbitrary. If the extent of chemoresponse to 
NAC was regarded as a continuous variable in this study, this 
study would have been much more informative.
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In reply: We thank Dr. Sokbom Kang for his interest in our 
investigation and his kind remarks. Obviously patients se-
lected for neoadjuvant chemotherapy (NAC) are a selected 
unfavorable group of ovarian cancer patients. The advantage 
of this approach as we have mentioned in our paper include 
an increased rate of optimal residual disease, less extensive 
surgery, reduced blood loss, lower morbidity, shortened hos-
pital stay and improved quality of life. In spite of these advan-
tages, NAC has not been shown to be superior with regard to 
outcome over up front surgery. It has only been shown not 
to be inferior to up front surgery [1]. The high rate of optimal 
cytoreduction in the total group (<0.5 cm in 86.5%) precluded 
a meaningful comparison between the rate of successful cyto-
reduction between good and poor responders, in our limited 
number of patients. Indeed as the Dr. Sokbom Kang noted “all 
patients may be similarly benefited by NAC in terms of surgi-
cal respectability”.
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